Australia's TGA updates risk management strategy with biologicals regulatory framework
This article was originally published in SRA
Australia's Therapeutic Goods Administration has updated a document that outlines its broad risk management strategy for therapeutic goods to include the new biologicals regulatory framework that came into effect on 31 May1,2. The framework covers human tissues and cellular therapies3.
You may also be interested in...
A new draft guideline explains how sponsors of subsequent-entry orally inhaled drug products can comply with the Canadian requirement for demonstrating equivalence to the reference product.
While good clinical practice inspectors in the UK and the US collaborate on matters of common interest, they say that mutual recognition is simply not possible.
Whoever takes over as chair of the Medicines and Healthcare products Regulatory Agency will play a key role in its plans to deliver a program of “ambitious business change.”